Beyond Air(US:XAIR)2025-11-14 21:30Revenue Performance - Revenue increased by 128% year over year to $1.8 million for the fiscal quarter ended September 30, 2025, compared to $0.8 million for the same period last year[8] - Revenues for the three months ended September 30, 2025, were $1,818,000, compared to $798,000 for the same period in 2024, representing a 128% increase[32] - Updated fiscal year 2026 revenue guidance to $8 - $10 million[19] Expenses and Losses - Gross loss decreased to $0.3 million for the quarter ended September 30, 2025, compared to a gross loss of $1.1 million for the same period last year[11] - Research and development expenses decreased to $2.5 million for the quarter ended September 30, 2025, from $4.6 million for the same period last year[12] - Selling, general and administrative expenses decreased to $4.9 million for the quarter ended September 30, 2025, compared to $7.2 million for the same period last year[13] - Net loss attributed to common stockholders was ($7.9) million or a loss of ($1.25) per share for the quarter ended September 30, 2025, compared to a net loss of ($13.4) million or ($5.67) per share for the same period last year[15] - The net loss attributable to Beyond Air, Inc. for the three months ended September 30, 2025, was $7,940,000, compared to $13,358,000 for the same period in 2024, reflecting a 41% decrease[32] Cash and Assets - Proforma cash, cash equivalents, restricted cash, and marketable securities totaled $22.9 million as of September 30, 2025[1] - Cash and cash equivalents increased to $9,699,000 as of September 30, 2025, from $4,665,000 as of March 31, 2025[33] - Total assets as of September 30, 2025, were $30,965,000, compared to $30,062,000 as of March 31, 2025, showing a growth of 3%[33] Operating Expenses - Total operating expenses for the three months ended September 30, 2025, were $7,363,000, down from $11,748,000 in the same period of 2024, indicating a 37% reduction[32] - Research and development expenses for the six months ended September 30, 2025, were $5,536,000, down from $10,594,000 in the same period of 2024, a reduction of 48%[32] Distribution and Designation - The company expanded its global LungFit PH distribution network to 35 countries, covering a combined population of 2.8 billion people[8] - The U.S. FDA granted Orphan Drug Designation to investigational therapies BA-101 and BA-102 for the treatment of Glioblastoma and Phelan-McDermid Syndrome, respectively[16] Other Financial Metrics - Net cash burn for the quarter ended September 30, 2025, was $4.7 million[17] - The weighted average number of shares outstanding for the three months ended September 30, 2025, was 6,356,573, compared to 2,355,927 for the same period in 2024, indicating a significant increase in shares[32] - The total liabilities as of September 30, 2025, were $17,870,000, an increase from $15,721,000 as of March 31, 2025[33] - The company reported a foreign currency translation loss of $18,000 for the three months ended September 30, 2025[32]